A Study on the Prevalence of Co-morbidities among the Patients with Chronic Kidney Disease
DOI:
https://doi.org/10.61427/jcpr.v4.i3.2024.124Keywords:
Chronic Kidney Disease, Diabetes, HypertensionAbstract
Aim: The main aim of this study is to assess the prevalence of various co-morbidities among the patients with chronic kidney disease.
Methods: This was a prospective study conducted for a period of six months at a tertiary care hospital of East Godavari district, Andhra Pradesh. Patients with both the genders who were diagnosed with CKD with an age of above 18 years were included and patients with acute renal failure were excluded from this study.
Results: In this study, most of the study participants were observed with stage-V CKD (80.4%) followed by stage-IV CKD (12.1%). Nephropathy due to hypertension (45.1%) and diabetes (24.3%) were observed to be the most common causes among the CKD patients in this study. Hypertension associated with diabetes (29.3%) was observed to be the most common co-morbidities in this study. Loop diuretics (43.7%) and calcium channel blockers (32.1%) were observed to be the most commonly prescribed anti-hypertensive drugs among the CKD patients associated with hypertension. Short acting insulin (71%) and sulfonyl ureas (13.1%) were observed to be the most commonly prescribed anti-diabetic drugs among the CKD patients associated with diabetes.
Conclusion: Routine screening and regular check-ups along with effective management of co-morbidities in CKD require a comprehensive approach that integrates the pharmacotherapy and inter-disciplinary collaboration. Clinical pharmacists should employ evidence-based practices, monitor drug interactions and advocate for patient-centred care to enhance the quality of life of CKD patients.
Downloads
References
Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan; 3(1):19-62.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6): 2089-100.
Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. J Clin Hypertens (Greenwich). 202; 23(4):831-834.
Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J,et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; 111: 4-9.
Rumeyza K. Risk factors for chronic kidney disease: An update. Kidney International Supplements, 2013; 3(4): 368-71.
Hsu RK, Hsu CY. The Role of Acute Kidney Injury in Chronic Kidney Disease. Semin Nephrol. 2016; 36(4):283-92.
Lee WC, Lee YT, Li LC, Ng HY, Kuo WH, Lin PT, Liao YC, Chiou TT, Lee CT. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3?5 Chronic Kidney Disease. J Clin Med. 2018; 7(12):493.
Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: A cohort study. Anna Int Med 2011; 154: 12.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med. 2004; 351: 1296-370.
Dasari Pranavi, Konuru Venkateswarlu, Venisetty Raj Kumar. Management of co-morbidities in chronic kidney disease: A prospective observational study. International Journal of Pharmacy and Pharmaceutical Sciences. 2014; 6: 363-67.
Published
How to Cite
Issue
Section
Copyright (c) 2024 K. Pushpavalli, S.T.P Prasuna , V. Bhavana Priya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.